These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35350744)

  • 1. PKQuest: PBPK modeling of highly lipid soluble and extracellular solutes.
    Levitt DG
    ADMET DMPK; 2019; 7(1):60-75. PubMed ID: 35350744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of the interstitial space in humans.
    Levitt DG
    BMC Clin Pharmacol; 2003 Jul; 3():3. PubMed ID: 12890292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics.
    Levitt DG
    BMC Anesthesiol; 2002 Aug; 2(1):5. PubMed ID: 12182764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKQuest_Java: free, interactive physiologically based pharmacokinetic software package and tutorial.
    Levitt DG
    BMC Res Notes; 2009 Aug; 2():158. PubMed ID: 19656378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human physiologically based pharmacokinetic model for propofol.
    Levitt DG; Schnider TW
    BMC Anesthesiol; 2005 Apr; 5(1):4. PubMed ID: 15847680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of human adipose blood flow.
    Levitt DG
    BMC Clin Pharmacol; 2007 Jan; 7():1. PubMed ID: 17239252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol.
    Levitt DG
    BMC Clin Pharmacol; 2002 Aug; 2():5. PubMed ID: 12182760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.
    Levitt DG
    BMC Clin Pharmacol; 2004 Feb; 4():2. PubMed ID: 15053829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.
    Levitt DG
    BMC Clin Pharmacol; 2002 Sep; 2():7. PubMed ID: 12323078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the Impact of Partition Coefficient Prediction Methods on Physiologically Based Pharmacokinetic Model Output Using a Standardized Tissue Composition.
    Utsey K; Gastonguay MS; Russell S; Freling R; Riggs MM; Elmokadem A
    Drug Metab Dispos; 2020 Oct; 48(10):903-916. PubMed ID: 32665416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution.
    Yau E; Olivares-Morales A; Gertz M; Parrott N; Darwich AS; Aarons L; Ogungbenro K
    AAPS J; 2020 Feb; 22(2):41. PubMed ID: 32016678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.
    Poulin P; Theil FP
    J Pharm Sci; 2000 Jan; 89(1):16-35. PubMed ID: 10664535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of partition coefficients in flow-limited physiologically-based pharmacokinetic modeling.
    Thompson MD; Beard DA; Wu F
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):313-27. PubMed ID: 22639356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound.
    Yun YE; Cotton CA; Edginton AN
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):1-14. PubMed ID: 24258064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.
    Björkman S
    J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):285-307. PubMed ID: 14650375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.
    Knaak JB; Dary CC; Zhang X; Gerlach RW; Tornero-Velez R; Chang DT; Goldsmith R; Blancato JN
    Rev Environ Contam Toxicol; 2012; 219():1-114. PubMed ID: 22610175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Extracellular Binding Proteins in the Cellular Uptake of Drugs: Impact on Quantitative In Vitro-to-In Vivo Extrapolations of Toxicity and Efficacy in Physiologically Based Pharmacokinetic-Pharmacodynamic Research.
    Poulin P; Burczynski FJ; Haddad S
    J Pharm Sci; 2016 Feb; 105(2):497-508. PubMed ID: 26173749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.